Objectives Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer, and successful eradication reduces long-term cancer incidence. Since national insurance coverage expanded in Japan in 2013, to include H. pylori-positive gastritis, eradication therapy has become widely accessible; however, outcomes may vary with antimicrobial resistance, evolving treatment regimens, and regional prescribing patterns. We investigated 10-year trends in eradication efficacy at a regional hospital in Japan.
SHIMADA et al. (2026) studied this question.